Scarica l'app Stockscreener
117.12
3.34%
3.79
Pre-mercato:
117.39
0.27
+0.23%
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Is FDA’s First-Ever Approval of Modeyso Shaping the Investment Case for Jazz Pharmaceuticals (JAZZ)? - simplywall.st
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.
Jazz Pharma wins FDA nod for Modeyso against rare brain tumor - MSN
Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance - MSN
Using flow based indicators on Jazz Pharmaceuticals plcTechnical Analysis of Growth Stock Opportunities - Newser
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Jazz Pharmaceuticals gets EU nod for Ziihera - MSN
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock - Yahoo Finance
FDA Grants Accelerated Approval to Dordaviprone For Diffuse Midline Glioma - Pharmacy Times
How to integrate Jazz Pharmaceuticals plc into portfolio analysis tools - Newser
Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted - insights.citeline.com
Jazz Pharmaceuticals stock surges 4.8% on FDA approval for Modeyso treatment - AInvest
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2025 Earnings Call Transcript - Insider Monkey
FDA approval of Modeyso for glioma - The Pharma Letter
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut - MSN
FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy - Pharmaceutical Technology
Beyond the Balance Sheet: What SWOT Reveals About Jazz Pharmaceu - GuruFocus
Jazz Earnings: Xywav and Epidiolex Drive Growth; US Approval for Chimerix's Dordaviprone Promising - Morningstar
Chimerix buyout a win for Jazz with FDA nod for rare glioma drug - BioWorld MedTech
US FDA approves Jazz Pharma's drug for rare brain tumor - Reuters
Rising Star: Quinn Emanuel's Frank Calvosa - Law360
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma - PR Newswire
Jazz Pharmaceuticals plc SEC 10-Q Report - TradingView
What data driven models say about Jazz Pharmaceuticals plc’s futureFree Triple Digit Return Stock Predictions - Newser
Jazz Pharmaceuticals plc 2025 Q2ResultsEarnings Call Presentation (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... By GuruFocus - Investing.com Canada
Jazz: Q2 Earnings Snapshot - Greenwich Time
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... - Yahoo Finance
Jazz Pharmaceuticals plc Earnings Report Breakdown: What Investors Should KnowTechnical Analysis of Growth Stock Opportunities - Newser
Using data tools to time your Jazz Pharmaceuticals plc exitFree Wealth Building Stock Market Ideas - Newser
Jazz Pharmaceuticals Reports Q2 2025 Results and CEO Transition - TipRanks
Jazz Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Jazz Pharmaceuticals Sticks To Its Game Plan Despite Setbacks - Finimize
Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Jazz Pharmaceuticals PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Jazz Pharmaceuticals plc, Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Jazz Pharmaceuticals misses on Q2 earnings, shares fall By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals misses on Q2 earnings, shares fall - Investing.com
Jazz Pharma earnings missed by $0.63, revenue topped estimates - Investing.com South Africa
Jazz Pharmaceuticals Q2 revenue up 2% - MarketScreener
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q2 Adjusted Loss $8.25 per Share, vs. FactSet Est Loss of $7.61 - MarketScreener
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance - PR Newswire
Narcolepsy Market to Reach New Heights in Growth by 2034, - openPR.com
Narcolepsy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts| Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical - Barchart.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) investors are sitting on a loss of 25% if they invested three years ago - Yahoo Finance
Jazz Pharmaceuticals Reports $1.05B Q2 Earnings, Appoints New CEO and Secures FDA Priority Review - Stock Titan
How Jazz Pharmaceuticals plc stock reacts to Fed policy changesSwing Entry Insight With Forecast Accuracy - Newser
What MACD signals say about Jazz Pharmaceuticals plcOversold Opportunity Scanner with RSI Data - Newser
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):